Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cortexyme, Inc.
Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Even though half of the drug developers that have gone public in the US during the first two quarters of the year are providing negative returns, the 13 companies trading in positive territory bring the class of 2019's average return to 10%.
Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing